Swaziland
Tuberculosis profile
| High HIV burden |
Population  2012 1.2 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.78 (0.031–2.7) 63 (2.5–219)
Mortality (HIV+TB only) 4.3 (4–5.1) 350 (321–410)
Prevalence  (includes HIV+TB) 11 (2.9–25) 907 (232–2 027)
Incidence  (includes HIV+TB) 17 (14–20) 1 349 (1 114–1 606)
Incidence (HIV+TB only) 13 (11–15) 1 037 (856–1 235)
Case detection, all forms (%) 43 (36–52)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 2 548 (37) Relapse 297 (34)
Smear-negative 1 539 (22) Treatment after failure 10 (1)
Smear-unknown / not done 1 572 (23) Treatment after default 22 (3)
Extrapulmonary 1 209 (18) Other 542 (62)
Other 0 (0)      
Total new 6 868   Total retreatment 871  
           
Other (history unknown) 0        
Total new and relapse 7 165   Total cases notified 7 739  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.0 1.1 1.1
Age < 15 57 660 68
Laboratories 2012
Smear (per 100 000 population) 1.5
Culture (per 5 million population) 4.1
Drug susceptibility testing (per 5 million population) 4.1
Is second-line drug susceptibility testing available? Yes, outside
country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 73   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 71  
Retreatment 59  
TB/HIV 2012 Number (%)
TB patients with known HIV status 7 363 (95)
HIV-positive TB patients 5 666 (77)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 5 559 (98)
HIV-positive TB patients on antiretroviral therapy (ART) 3 762 (66)
HIV-positive people screened for TB 69 302  
HIV-positive people provided with IPT 1 934  
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 7.7 (4.8–11) 34 (28–39)
MDR-TB cases among notified pulmonary
TB cases
430 (270–590) 290 (250–340)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB      
Laboratory-confirmed MDR-TB cases     280
Patients started on MDR-TB treatment     484
Financing TB control 2013
National TB programme budget (US$ millions) 23
% Funded domestically 10%
% Funded internationally 29%
% Unfunded 62%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-23 Data: www.who.int/tb/data